Regular ArticleA One-Step Fluorometric Method for the Continuous Measurement of Monoamine Oxidase Activity☆
Abstract
We have developed a one-step fluorometric method for the measurement of monoamine oxidase (MAO) activity in 96-well microplates with sensitivity 10-fold higher than the conventional spectrophotometric assay method. This assay is based on the detection of H2O2in a horseradish peroxidase-coupled reaction usingN-acetyl-3,7-dihydroxyphenoxazine (Amplex Red), a highly sensitive and stable probe for H2O2. With a single sampling, this assay is useful for performing both end-point and continuous measurements of MAO activity. Using a commercially available enzyme, our assay allows the detection of MAO B activity as low as 1.2 × 10−5U/ml. When applied to crude tissue homogenates, we have been able to selectively detect both MAO A and MAO B from cow brain tissue with protein content as low as 200 μg per sample. The potential applications of this assay include the measurement of MAO activity in normal and diseased tissues, blood samples, and other biological fluids and the screening of drugs for the treatment of MAO-mediated diseases.
References (18)
- J.L. Ives et al.
Annu. Rep. Med. Chem.
(1989) - L.Y. Zang et al.
J. Biol. Chem.
(1993) - D.A Averill-Bates et al.
Arch. Biochem. Biophys.
(1993) - R. Stevanato et al.
Arch. Biochem. Biophys.
(1995) - J.P. Zhou et al.
Anal. Biochem.
(1996) - K. Takagi et al.
Clin. Chim. Acta
(1994) - L. Dini et al.
Biochem. Biophys. Res. Commun.
(1991) - M.B.H. Youdim et al.
Methods Enzymol.
(1987)
Cited by (182)
An in situ fluorescent copolymer dots-based kit for the specific detection of monoamine oxidase-A in cell/tissue/human prostate cancer
2023, Sensors and Actuators B: ChemicalCurrently, the development of simple, fast, low-cost, and environmentally friendly MAO-A specific detection methods remains a huge challenge. Herein, a simple in situ fluorescent copolymer dots (FCDs)-based kit is constructed for the specific detection of monoamine oxidase-A in cell, tissue and human prostate cancer. The developed kit is depended on the high reaction activity between epinephrine and polyethyleneimine to form FCDs and the selective catalyzing activity of MAO-A on epinephrine. The gained FCDs are identified and characterized by high-resolution TEM, absorption and fluorescence spectrum. The present kit achieves highly sensitive detection of MAO-A with a limit of detection (LOD) of 20 ng/mL as well as screening of inhibitor with an IC50 (the concentration responding to 50% inhibition) of 1.071 μM by using clorgyline as a model. The MAO-A and MAO-B as the two isoforms of MAO are discriminated successfully, demonstrating the excellent selectivity of our kit. Noteworthy, the proposed method is applicable for measuring MAO-A not only from serum samples, but also for endogenous MAO-A in cells, mouse tissues and human prostate tumors with satisfied results. The proposed kit will be a great potential tool for human prostate cancer (PCa) diagnosis and the development of anti-PCa drug screening.
The colors of peroxygenase activity: Colorimetric high-throughput screening assays for directed evolution
2023, Methods in EnzymologyFungal unspecific peroxygenases (UPOs) are arising as versatile biocatalysts for C–H oxyfunctionalization reactions. In recent years, several directed evolution studies have been conducted to design improved UPO variants. An essential part of this protein engineering strategy is the design of reliable colorimetric high-throughput screening (HTS) assays for mutant library exploration. Here, we present a palette of 12 colorimetric HTS assays along with their step-by-step protocols, which have been validated for directed UPO evolution campaigns. This array of colorimetric assays will pave the way for the discovery and design of new UPO variants.
Looking at LPMO reactions through the lens of the HRP/Amplex Red assay
2023, Methods in EnzymologyLytic polysaccharide monooxygenases (LPMOs) are unique redox enzymes capable of disrupting the crystalline surfaces of industry-relevant recalcitrant polysaccharides, such as chitin and cellulose. Historically, LPMOs were thought to be slow enzymes relying on O2 as the co-substrate, but it is now clear that these enzymes prefer H2O2, allowing for fast depolymerization of polysaccharides through a peroxygenase reaction. Thus, quantifying H2O2 in LPMO reaction set-ups is of a great interest. The horseradish peroxidase (HRP)/Amplex Red (AR) assay is one of the most popular and accessible tools for measuring hydrogen peroxide. This assay has been used in various types of biological and biochemical studies, including LPMO research, but suffers from pitfalls that need to be accounted for. In this Chapter, we discuss this method and its use for assessing the often rate-limiting in situ formation of H2O2 in LPMO reactions. We show that, after accounting for multiple potential side reactions, quantitative data on H2O2 production obtained with the HRP/Amplex Red assay provide useful clues for understanding the catalytic activity of LPMOs, including the impact of reductants and transition metal ions.
The inhibition of monoamine oxidase by 2H-1,4-benzothiazin-3(4H)-ones
2022, Bioorganic and Medicinal Chemistry LettersMonoamine oxidase (MAO) plays an important role in psychiatric and neurological disorders, such as depression and Parkinson's disease. As a result, MAO represents a key target for developing drugs to treat these conditions. The present study aimed to synthesise and discover compounds that inhibit the MAO enzymes and which may be relevant to the treatment of neurological disorders. A series of nine 2H-1,4-benzothiazin-3(4H)-ones were synthesised and evaluated as potential in vitro inhibitors of human MAO-A and MAO-B. The benzothiazinones bear structural similarity to a series of 3,4-dihydro-2(1H)-quinolinones that have been shown to be highly potent MAO-B inhibitors. The results show that the benzothiazinones inhibit both MAO isoforms but are more potent MAO-B inhibitors. The most potent inhibitors exhibit IC50 values of 0.0027 (1b), 0.0082 (1c), 0.0096 (1d), and 0.0041 µM (1h) for MAO-B, and 0.714 µM (1d) for MAO-A. These benzothiazinone derivatives exhibit promising MAO inhibition activities and may be developed into clinically useful agents for the treatment of Parkinson’s disease. Interestingly, related 4H-3,1-benzothiazin-4-ones have previously been investigated as dual-target-directed drugs that inhibit MAO-B and antagonize adenosine A2A receptors for the treatment of Parkinson’s disease. Based on an interest in d-amino acid oxidase (DAAO) as a target for the treatment for schizophrenia, the 2H-1,4-benzothiazin-3(4H)-ones were also evaluated as in vitro inhibitors of this enzyme. Among the study compounds, only 7-hydroxy-2H-1,4-benzothiazin-3(4H)-one (IC50 = 4.20 µM) was an active DAAO inhibitor. Finally, molecular docking was employed to gain insight into the binding modes and interactions of the 2H-1,4-benzothiazin-3(4H)-ones with MAO.
Isatoic anhydrides as novel inhibitors of monoamine oxidase
2022, Bioorganic and Medicinal ChemistryThe monoamine oxidase (MAO) enzymes metabolise neurotransmitter amines in the central and peripheral tissues, and thereby contribute to the regulation of neurotransmission. Inhibitors of MAO modulate the levels of neurotransmitters in the central nervous system, and have been used for several decades for the treatment of depression and Parkinson’s disease, while potential new therapeutic applications in other diseases such as prostate cancer and heart failure may exist. In the interest of discovering new classes of chemical compounds that potently inhibit the MAOs, the present study synthesises a series of ten isatoic anhydrides and evaluates their potential as in vitro inhibitors of human MAO-A and MAO-B. The isatoic anhydrides bear structural similarity to a series of 3,4-dihydro-2(1H)-quinolinones as well as to series of isatins and phthalimides that have been reported to act as potent MAO-B inhibitors. The results document that the isatoic anhydrides inhibit both MAO isoforms with the most potent inhibitors exhibiting IC50 values of 0.010 µM (1b and 1h) and 0.0047 µM (1j) for MAO-A and MAO-B, respectively. Molecular docking suggests that isatoic anhydrides exhibit similar binding modes and interactions with MAO-A and MAO-B, which may explain their potent inhibition of both isoforms. It may be concluded that the isatoic anhydrides represent a new class of MAO inhibitors, while it is interesting to note that very few studies on the pharmacological actions of isatoic anhydrides have been reported. As a secondary aim, the isatoic anhydrides were also evaluated as potential inhibitors of d-amino acid oxidase (DAAO), acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).
Coumarin derivatives as inhibitors of D-amino acid oxidase and monoamine oxidase
2022, Bioorganic Chemistryd-Amino acid oxidase (DAAO) oxidises d-amino acids to ultimately produce the corresponding α-keto acids. The DAAO substrate, d-serine, is a co-agonist at NMDA receptors, while NMDA receptor hypo-function has been implicated in the pathophysiology of schizophrenia. Through the modulation of d-serine levels, the inhibition of DAAO represents a strategy to increase NMDA receptor function, and thus a potential treatment for schizophrenia. Literature reports that 3-hydroxycoumarin is a potent inhibitor of DAAO and represents an ideal lead for the development of novel DAAO inhibitors. Based on this, the present study investigated DAAO inhibition by a series of synthetic and commercially available coumarin derivatives. Due to structural similarity to coumarin, a synthetic series of 3,4-dihydroisoquinolin-1(2H)-one derivatives has also been included in this study. The results show that among 37 compound evaluated, four inhibit porcine kidney DAAO with IC50 < 10 µM. The most potent inhibitors are 3,7-dihydroxycoumarin and 6,7-dihydroxycoumarin with an IC50 values of 0.167 and 0.224 µM, respectively. These values are an improvement on that of the reference DAAO inhibitor, 3-methylpyrazole-5-carboxylic acid (IC50 = 1.88 µM). Coumarin compounds are also known to inhibit the monoamine oxidase (MAO) enzymes, which are well established targets for the treatment of depression and Parkinson’s disease. As DAAO and MAO are flavoenzymes, off-target inhibition may occur. The series were thus evaluated as potential MAO inhibitors, and a number of high potency inhibitors were identified. Seven compounds inhibit the recombinant human MAOs with IC50 < 0.1 µM, with the most potent MAO-A and MAO-B inhibitors exhibiting IC50 values of 0.033 and 0.012 µM, respectively. This is significantly more potent than the reference inhibitors, curcumin, isatin and toloxatone. This study concludes that active DAAO and MAO inhibitors may serve as novel leads for the design of compounds that may find future application in the treatment of neuropsychiatric (e.g. schizophrenia, depression) and neurodegenerative disorders (e.g. Parkinson’s disease).
- ☆
R. J. Beynon, Ed.